selvigaltin

Selvigaltin is an orally active small‑molecule inhibitor of galectin‑3, a β‑galactoside–binding lectin implicated in fibrosis, inflammation, and tumor immune evasion.[13][4] Developed by Galecto, it is the first highly effective oral galectin‑3 inhibitor, with nanomolar affinity, good selectivity, and high oral bioavailability in animals and humans.[4][16][15] By blocking galectin‑3, selvigaltin reduces hepatic steatosis, inflammation, and fibrosis in preclinical metabolic dysfunction–associated steatohepatitis models and improves liver biomarkers in patients with cirrhosis, and it is being clinically evaluated in liver cirrhosis/fibrosis as well as oncology indications including non‑small cell lung cancer, metastatic melanoma, and head and neck squamous cell carcinoma, both alone and in combination with immune checkpoint inhibitors or other standard regimens.[13][1][7][4][9]

Other names

galectin-3 inhibitorgalectin3 inhibitorgalectin 3 inhibitorgalectin-3 modulatorgalectin3 modulatorgalectin 3 modulator